[{"id":"78af9b6a-0b92-4e92-b86c-385f5f7643c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04266912","created_at":"2021-01-18T20:43:57.460Z","updated_at":"2025-02-25T14:15:34.609Z","phase":"Phase 1/2","brief_title":"Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors","source_id_and_acronym":"NCT04266912","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • ATM • ARID1A • BAP1 • MSH2 • CDK12 • ATRX • CHEK2 • SMARCB1 • RAD51 • FANCA • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • ATM • ARID1A • BAP1 • MSH2 • CDK12 • ATRX • CHEK2 • SMARCB1 • RAD51 • FANCA • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • berzosertib (M6620)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/17/2020","start_date":" 03/17/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-18"},{"id":"7764dbff-7eb4-429d-95dc-1ab78ecc2834","acronym":"SOLARA","url":"https://clinicaltrials.gov/study/NCT04711824","created_at":"2021-01-19T20:52:35.671Z","updated_at":"2025-02-25T14:59:38.736Z","phase":"Phase 1/2","brief_title":"Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases","source_id_and_acronym":"NCT04711824 - SOLARA","lead_sponsor":"Colette Shen","biomarkers":" HER-2 • BRCA","pipe":" | ","alterations":" HER-2 negative • BRCA mutation","tags":["HER-2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 03/09/2022","start_date":" 03/09/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-11-22"},{"id":"f6e94490-8464-4ca1-871d-9dfc5c85f532","acronym":"DAPPER","url":"https://clinicaltrials.gov/study/NCT03851614","created_at":"2021-01-18T19:00:33.382Z","updated_at":"2025-02-25T15:08:21.640Z","phase":"Phase 2","brief_title":"Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03851614 - DAPPER","lead_sponsor":"University Health Network, Toronto","biomarkers":" HRD • CD4","pipe":"","alterations":" ","tags":["HRD • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 04/08/2019","start_date":" 04/08/2019","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-03-15"},{"id":"8eae4547-c419-42bc-bcef-a0c556fe5a48","acronym":"REVOCAN","url":"https://clinicaltrials.gov/study/NCT04826198","created_at":"2021-04-01T16:52:33.019Z","updated_at":"2024-07-02T16:35:51.390Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months","source_id_and_acronym":"NCT04826198 - REVOCAN","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" BRCA • MUC16","pipe":"","alterations":" ","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Zejula (niraparib) • Rubraca (rucaparib) • AsiDNA (etidaligide)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 10/05/2020","start_date":" 10/05/2020","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2023-04-05"},{"id":"d8f465db-29ac-4ca7-bf00-d3ee8cdb5495","acronym":"","url":"https://clinicaltrials.gov/study/NCT05700669","created_at":"2023-01-26T15:02:54.849Z","updated_at":"2024-07-02T16:35:51.737Z","phase":"Phase 1b/2","brief_title":"Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors","source_id_and_acronym":"NCT05700669","lead_sponsor":"Onxeo","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • AsiDNA (etidaligide)"],"overall_status":"Recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 02/20/2023","start_date":" 02/20/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2023-03-31"}]